Vyne Therapeutics Inc.
13F holders, Q2 2024 (June 30)2holders
1new positions
1sold out
$1.97avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, unchanged from Q1 2024. 1 opened new positions and 1 sold out. The largest holders were Staley Capital Advisers Inc. ($72K) and Ashton Thomas Private Wealth, LLC ($37).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $37 |
| Exits | 1 | $6 |
All 13F filers, Q1 2024 → Q2 2024: 19 shares bought and 2 shares sold, net +17 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Staley Capital Advisers Inc. | 0.00% | No change | 36,472 | $72K |
| Ashton Thomas Private Wealth, LLC | 0.00% | New | 19 | $37 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.